Rabbit anti-Human MED17 Polyclonal Antibody | anti-MED17 antibody
MED17, ID (MED17, ARC77, CRSP6, DRIP77, DRIP80, TRAP80, Mediator of RNA polymerase II transcription subunit 17, Activator-recruited cofactor 77kD component, Cofactor required for Sp1 transcriptional activation subunit 6, Mediator complex subunit 17, Thyro
ELISA: 1:1,000
Applications are based on unconjugated antibody.
NCBI and Uniprot Product Information
NCBI Description
The activation of gene transcription is a multistep process that is triggered by factors that recognize transcriptional enhancer sites in DNA. These factors work with co-activators to direct transcriptional initiation by the RNA polymerase II apparatus. The protein encoded by this gene is a subunit of the CRSP (cofactor required for SP1 activation) complex, which, along with TFIID, is required for efficient activation by SP1. This protein is also a component of other multisubunit complexes e.g. thyroid hormone receptor-(TR-) associated proteins which interact with TR and facilitate TR function on DNA templates in conjunction with initiation factors and cofactors. [provided by RefSeq, Jul 2008]
Uniprot Description
MED17: Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors. Defects in MED17 are the cause of microcephaly postnatal progressive with seizures and brain atrophy (MCPHSBA). It is a disorder characterized by postnatal progressive microcephaly and severe developmental retardation associated with cerebral and cerebellar atrophy. Infants manifest swallowing difficulties leading to failure to thrive, jitteriness, poor visual fixation, truncal arching, seizures. There is no acquisition of developmental milestones and patients suffer from marked spasticity and profound retardation. Progressive microcephaly becomes evident few months after birth. Belongs to the Mediator complex subunit 17 family. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Transcription, coactivator/corepressor; Nuclear receptor co-regulator
Chromosomal Location of Human Ortholog: 11q14
Cellular Component: nucleoplasm; transcription factor complex; membrane; Srb-mediator complex; nucleus
Molecular Function: protein binding; ligand-dependent nuclear receptor transcription coactivator activity; vitamin D receptor binding; transcription coactivator activity; transcription cofactor activity; receptor activity; thyroid hormone receptor binding
Biological Process: steroid hormone receptor signaling pathway; regulation of transcription from RNA polymerase II promoter; transcription initiation from RNA polymerase II promoter; positive regulation of transcription, DNA-dependent; stem cell maintenance; androgen receptor signaling pathway; gene expression; positive regulation of transcription from RNA polymerase II promoter
Disease: Microcephaly, Postnatal Progressive, With Seizures And Brain Atrophy
Research Articles on MED17
Similar Products
Product Notes
The MED17 med17 (Catalog #AAA6319961) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The MED17, ID (MED17, ARC77, CRSP6, DRIP77, DRIP80, TRAP80, Mediator of RNA polymerase II transcription subunit 17, Activator-recruited cofactor 77kD component, Cofactor required for Sp1 transcriptional activation subunit 6, Mediator complex subunit 17, Thyro reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's MED17 can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB), ELISA (EIA). WB: 1:100-500 ELISA: 1:1,000 Applications are based on unconjugated antibody. Researchers should empirically determine the suitability of the MED17 med17 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "MED17, Polyclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.